Abstract:Background & aims: β-blockers reduce hepatic venous pressure gradient (HVPG) by decreasing portal inflow, with no reduction in intrahepatic vascular resistance. 5-Methyltetrahydrofolate (5-MTHF) can prevent oxidative loss of tetrahydrobiopterin (BH4), a cofactor for endothelial nitric oxide synthase coupling. It also converts homocysteine (tHcy) into methionine and enables the degradation of asymmetric dimethylarginine (ADMA), an inhibitor of endothelial nitric oxide synthase. The aim of this study was to evaluate the effects of 5-MTHF in combination with propranolol on HVPG and nitric oxide bioavailability markers in patients with cirrhosis and portal hypertension. Method: Sixty patients with cirrhosis and HVPG ≥12 mmHg were randomized 1:1 to receive treatment with 5-MTHF+propranolol or placebo+propranolol for 90 days under double-blind conditions. HVPG and markers of nitric oxide bioavailability (BH4, ADMA and tHcy) were measured again at the end of treatment. Results: Groups were similar in terms of baseline clinical and hemodynamic data and nitric oxide bioavailability markers. HVPG decreased in both groups, but the magnitude of the change was significantly greater in the group treated with 5-MTHF+propranolol compared to placebo+propranolol (percentage decrease, 20 [29-9] vs. 12.5 [22-0], p = 0.028), without differences in hepatic blood flow. At the end of treatment, 5-MTHF+propranolol (vs. placebo+propranolol) was associated with higher BH4 (1,101.4 ± 1,413.3 vs. 517.1 ± 242.8 pg/ml, p <0.001), lower ADMA (109.3 ± 52.7 vs. 139.9 ± 46.7 μmol/L, p = 0.027) and lower tHcy (μmol/L, 11.0 ± 4.6 vs. 15.4 ± 7.2 μmol/L, p = 0.010) plasma levels. Conclusion: In patients with cirrhosis and portal hypertension, 5-MTHF administration significantly enhanced the HVPG reduction achieved with propranolol. This effect appears to be mediated by improved nitric oxide bioavailability in the hepatic microcirculation. Clinical trial eudract number: 2014-002018-21. Impact and implications: Currently, the pharmacological prevention of cirrhosis complications due to portal hypertension, such as esophageal varices rupture, is based on the use of β-blockers, but some patients still present with acute variceal bleeding, mainly due to an insufficient reduction of portal pressure. In this study, we sought to demonstrate that the addition of folic acid to β-blockers is more effective in reducing portal pressure than β-blockers alone. This finding could represent the basis for validation studies in larger cohorts, which could impact the future prophylactic management of variceal bleeding in cirrhosis. Enhancing the benefit of β-blockers with a safe, accessible, cost-effective drug could improve clinical outcomes in cirrhosis, which in turn could translate into a reduction in the rates and costs of hospitalization, and ultimately into improved survival.

A Study of the Relationship between Serum Bile Acids and Propranolol Pharmacokinetics and Pharmacodynamics in Patients with Liver Cirrhosis and in Healthy Controls

Dose-dependent Effect of Propranolol on the Hemodynamic Response in Cirrhotic Patients with Gastroesophageal Varices

Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris.

Effect of Propranolol on Hemodynamics and Its Clinical Significance in Patients with Portal Hypertension

Influence of CYP2D6 and β2-adrenergic receptor gene polymorphisms on the hemodynamic response to propranolol in Chinese Han patients with cirrhosis.

Propranolol can correct prolonged QT intervals in patients with cirrhosis

The Clinical Significance of Propranolol in the Treatment of Thrombocytopenia in Patients with Cirrhosis

Effect of Antiorthostatic Hypokinesia on the Pharmacokinetics and Bioavailability of Propranolol

Effect factors analysis of propranolol decreasing hepatic venous pressure gradient in patients with liver cirrhosis

Octreotide and propranolol in treatment of liver cirrhosis combined with upper gastrointestinal hemorrhage and effects on hemodynamics

Study on the stereoselectivity of racemic propranolol glucuronidation metabolism

Stereoselectivity and Interaction Between the Glucuronidation of S-(-)- and R-(+)-Propranolol in Rat Hepatic Microsomes Pretreated with Different Inducers

5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial

Stereoselective Propranolol Metabolism in Two Drug Induced Rat Hepatic Microsomes

Lack of significant effect of therapeutic propranolol on measurable platelet function in healthy subjects.

Biophysical characterization of the drug-membrane interactions: the case of propranolol and acebutolol

Propranolol in the Prevention of the First Upper Gastrointestinal Bleeding in Patients with Cirrhosis: a Meta- Analysis

[Effects of Microsome Enzyme Induced by Phenobarbarbital on the Stereoselectivity of Recemic Propranolol Glucuronidation Metabolism].

Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: A pilot randomized controlled trial

No Correlation Between Side-Chain of Propranolol Oxidation and S-mephenytoin 4'-Hydroxylase Activity.

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.